A new strategy to fight antimicrobial resistance: The revival of old antibiotics

Frontiers in Microbiology

Volumn 5, Issue OCT, 2014, Pages

  Cassir, Nadim ^a   Rolain, Jean Marc ^a   Brouqui, Philippe ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CLINDAMYCIN; CLOFAZIMINE; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; FUSIDIC ACID; MECILLINAM; MINOCYCLINE; NITROFURANTOIN; PIVMECILLINAM; POLYMYXIN DERIVATIVE; PRISTINAMYCIN; RIFAMPICIN; TEMOCILLIN; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTERIAL GENE; BONE INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; LEPROSY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 84910091759     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2014.00551     Document Type: Note

References (210)

1. Aboltins, C. A., Page, M. A., Buising, K. L., Jenney, A. W. J., Daffy, J. R., Choong, P. F. M., and Stanley, P. A. (2007). Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin. Microbiol. Infect. 13, 586-591.
2. Adams-Haduch, J. M., Potoski, B. A., Sidjabat, H. E., Paterson, D. L., and Doi, Y. (2009). Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob. Agents Chemother.
3. Ahamed Puthiyaveetil, S. (2009). Osteomyelitis--a case report. Aust Fam Physician 38, 521- 523.
4. Ameen, S. M., and Drancourt, M. (2013). In Vitro Susceptibility of Mycobacterium tuberculosis to Trimethoprim and Sulfonamides in France. Antimicrob Agents Chemother 57, 6370-6371.
5. American Thoracic Society, and Infectious Diseases Society of America (2005). Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am. J. Respir. Crit. Care Med.
6. Andersson, D. I., and Hughes, D. (2010). Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol.
7. Apisarnthanarak, A., and Mundy, L. M. (2012). Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin. International Journal of Antimicrobial Agents 39, 271- 272.
8. Balakrishnan, I., Awad-El-Kariem, F. M., Aali, A., Kumari, P., Mulla, R., Tan, B., Brudney, D., Ladenheim, D., Ghazy, A., Khan, I., et al. (2011). Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother. 66, 2628-2631.
9. Barry, V. C., Belton, J. G., Conalty, M. L., Denneny, J. M., Edward, D. W., O'sullivan, J. F., Twomey, D., and Winder, F. (1957). A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature 179, 1013-1015.
10. Barton, E., Flanagan, P., and Hill, S. (2008). Spinal infection caused by ESBL-producing Klebsiella pneumoniae treated with temocillin. J. Infect. 57, 347-349.
11. Bassetti, M., Repetto, E., Righi, E., Boni, S., Diverio, M., Molinari, M. P., Mussap, M., Artioli, S., Ansaldi, F., Durando, P., et al. (2008). Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 61, 417- 420.
12. Bengtsson, E., Svanbom, M., and Tunevall, G. (1974). Trimethoprim-sulphamethoxazole treatment in staphylococcal endocarditis and gram-negative septicemia. Scand. J. Infect. Dis. 6, 177-182.
13. Betrosian, A. P., Frantzeskaki, F., Xanthaki, A., and Douzinas, E. E. (2008). Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J. Infect. 56, 432-436.
14. Biswas, S., Brunel, J.-M., Dubus, J.-C., Reynaud-Gaubert, M., and Rolain, J.-M. (2012). Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther 10, 917- 934.
15. Boelaert, J., Daneels, R., Schurgers, M., Lambert, A. M., Van Landuyt, H. W., Mellows, G., Wolf, J., and Swaisland, A. J. (1983). The pharmacokinetics of temocillin in patients with normal and impaired renal function. J. Antimicrob. Chemother. 11, 349-356.
16. Bosman, A. B., Wagenaar, J. A., Stegeman, J. A., Vernooij, J. C. M., and Mevius, D. J. (2014). Antimicrobial resistance in commensal Escherichia coli in veal calves is associated with antimicrobial drug use. Epidemiol. Infect. 142, 1893-1904.
17. De Boutin, J. L., Manuel, C., Charrel, J., Aubert, C., Mallet, M. N., Gevaudan, M. J., Malmejac, C., and Houel, J. (1985). [Value of the aminoglycoside-fosfomycin combination. Apropos of a case of bacterial endocarditis]. Pathol. Biol. 33, 684-686.
18. Brouqui, P., Aubry, C., Million, M., Drancourt, M., and Raoult, D. (2013). Totally resistant tuberculosis: will antileprosy drugs be helpful? Int. J. Antimicrob. Agents 42, 584-585.
19. Cadena, J., Nair, S., Henao-Martinez, A. F., Jorgensen, J. H., Patterson, J. E., and Sreeramoju, P. V. (2011). Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.
20. Cai, Y., Chai, D., Wang, R., Liang, B., and Bai, N. (2012). Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J. Antimicrob. Chemother. 67, 1607-1615.
21. Caminero, J. A., Sotgiu, G., Zumla, A., and Migliori, G. B. (2010). Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 10, 621- 629.
22. Caminero, J. A., World Health Organization, American Thoracic Society, and British Thoracic Society (2006). Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int. J. Tuberc. Lung Dis. 10, 829-837.
23. Campbell, M. L., Marchaim, D., Pogue, J. M., Sunkara, B., Bheemreddy, S., Bathina, P., Pulluru, H., Chugh, N., Wilson, M. N., Moshos, J., et al. (2012). Treatment of methicillinresistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents. Ann Pharmacother 46, 1587-1597.
24. Di Carlo, P., D'Alessandro, N., Guadagnino, G., Bonura, C., Mammina, C., Lunetta, M., Novo, S., and Giarratano, A. (2013). High dose of trimethoprim-sulfamethoxazole and daptomycin as a therapeutic option for MRSA endocarditis with large vegetation complicated by embolic stroke: a case report and literature review. Infez Med 21, 45-49.
25. Casalta, J.-P., Zaratzian, C., Hubert, S., Thuny, F., Gouriet, F., Habib, G., Grisoli, D., Deharo, J.-C., and Raoult, D. (2013). Treatment of Staphylococcus aureus endocarditis with high doses of trimethoprim/sulfamethoxazole and clindamycin-Preliminary report. Int. J. Antimicrob. Agents 42, 190-191.
26. Castanheira, M., Watters, A. A., Mendes, R. E., Farrell, D. J., and Jones, R. N. (2010). Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008). J. Antimicrob. Chemother. 65, 1353- 1358.
27. Cenizal, M. J., Skiest, D., Luber, S., Bedimo, R., Davis, P., Fox, P., Delaney, K., and Hardy, R. D. (2007). Prospective randomized trial of empiric therapy with trimethoprimsulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 51, 2628-2630.
28. Changchien, C.-H., Chen, Y.-Y., Chen, S.-W., Chen, W.-L., Tsay, J.-G., and Chu, C. (2011). Retrospective study of necrotizing fasciitis and characterization of its associated Methicillinresistant Staphylococcus aureus in Taiwan. BMC Infect Dis 11, 297.
29. Chen, A. E., Goldstein, M., Carroll, K., Song, X., Perl, T. M., and Siberry, G. K. (2006). Evolving epidemiology of pediatric Staphylococcus aureus cutaneous infections in a Baltimore hospital. Pediatr Emerg Care 22, 717-723.
30. Chiang, E.-R., Su, Y.-P., Chen, T.-H., Chiu, F.-Y., and Chen, W.-M. (2011). Comparison of articulating and static spacers regarding infection with resistant organisms in total knee arthroplasty. Acta Orthop 82, 460-464.
31. Clumeck, N., Marcelis, L., Amiri-Lamraski, M. H., and Gordts, B. (1984). Treatment of severe staphylococcal infections with a rifampicin-minocycline association. J. Antimicrob. Chemother. 13 Suppl C, 17-22.
32. Collins, L. A., Malanoski, G. J., Eliopoulos, G. M., Wennersten, C. B., Ferraro, M. J., and Moellering, R. C. (1993). In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob. Agents Chemother. 37, 598-601.
33. Conceição, N., Oliveira, C. da C. H. B. de, Silva, P. R. da, Avila, B. G. M., and Oliveira, A. G. de (2011). Trends in antimicrobial resistance among clinical isolates of enterococci in a Brazilian tertiary hospital: a 4-year study. Rev. Soc. Bras. Med. Trop. 44, 177-181.
34. Cooper, E. C., Curtis, N., Cranswick, N., and Gwee, A. (2014). Pristinamycin: old drug, new tricks? J. Antimicrob. Chemother.
35. Cunha, B. A. (2013). Minocycline, often forgotten but preferred to trimethoprimsulfamethoxazole or doxycycline for the treatment of community-acquired meticillin-resistant Staphylococcus aureus skin and soft-tissue infections. Int. J. Antimicrob. Agents 42, 497-499.
36. Cunha, B. A. (1989). Nitrofurantoin: an update. Obstet Gynecol Surv 44, 399-406.
37. Cunha, B. A., Schoch, P. E., and Hage, J. R. (2011). Nitrofurantoin: preferred empiric therapy for community-acquired lower urinary tract infections. Mayo Clin. Proc. 86, 1243-1244; author reply 1244.
38. Dancer, S. J., Robb, A., Crawford, A., and Morrison, D. (2003). Oral streptogramins in the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. J. Antimicrob. Chemother. 51, 731-735.
39. D'Costa, V. M., King, C. E., Kalan, L., Morar, M., Sung, W. W. L., Schwarz, C., Froese, D., Zazula, G., Calmels, F., Debruyne, R., et al. (2011). Antibiotic resistance is ancient. Nature 477, 457-461. doi:10.1038/nature10388.
40. Demers, P., Fraser, D., Goldbloom, R. B., Haworth, J. C., LaRochelle, J., MacLean, R., and Murray, T. K. (1968). Effects of tetracyclines on skeletal growth and dentition. A report by the Nutrition Committee of the Canadian Paediatric Society. Can Med Assoc J 99, 849-854.
41. Deshpande, L. M., Fritsche, T. R., Moet, G. J., Biedenbach, D. J., and Jones, R. N. (2007). Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. 58, 163-170.
42. Van Deun, A., Maug, A. K. J., Salim, M. A. H., Das, P. K., Sarker, M. R., Daru, P., and Rieder, H. L. (2010). Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182, 684-692.
43. Dewar, S., Reed, L. C., and Koerner, R. J. (2014). Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. J. Antimicrob. Chemother. 69, 303-308.
44. Diene, S. M., Merhej, V., Henry, M., El Filali, A., Roux, V., Robert, C., Azza, S., Gavory, F., Barbe, V., La Scola, B., et al. (2013). The rhizome of the multidrug-resistant Enterobacter aerogenes genome reveals how new "killer bugs" are created because of a sympatric lifestyle. Mol. Biol. Evol. 30, 369-383.
45. Diep, B. A., Chambers, H. F., Graber, C. J., Szumowski, J. D., Miller, L. G., Han, L. L., Chen, J. H., Lin, F., Lin, J., Phan, T. H., et al. (2008). Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann. Intern. Med. 148, 249-257.
46. Dinh, A., Salomon, J., Bru, J. P., and Bernard, L. (2012). Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand. J. Infect. Dis. 44, 182-189.
47. Drancourt, M., Stein, A., Argenson, J. N., Roiron, R., Groulier, P., and Raoult, D. (1997). Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J. Antimicrob. Chemother. 39, 235-240.
48. Dubourg, G., Lagier, J. C., Armougom, F., Robert, C., Hamad, I., Brouqui, P., and Raoult, D. (2013). The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics. Eur. J. Clin. Microbiol. Infect. Dis.
49. Duerinckx, J. F. H. (2008). Case Report: Subacute Synovitis of the Knee After a Rose Thorn Injury: Unusual Clinical Picture. Clin Orthop Relat Res 466, 3138-3142.
50. Falagas, M. E., Giannopoulou, K. P., Kokolakis, G. N., and Rafailidis, P. I. (2008). Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin. Infect. Dis. 46
51. Falagas, M. E., and Kasiakou, S. K. (2005). Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40
52. Falagas, M. E., and Kasiakou, S. K. (2006). Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10, R27.
53. Falagas, M. E., Kasiakou, S. K., Kofteridis, D. P., Roditakis, G., and Samonis, G. (2006a). Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 25, 596-599.
54. Falagas, M. E., Kastoris, A. C., Karageorgopoulos, D. E., and Rafailidis, P. I. (2009). Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int. J. Antimicrob. Agents 34, 111-120.
55. Falagas, M. E., and Kopterides, P. (2007). Old antibiotics for infections in critically ill patients. Curr Opin Crit Care 13, 592-597.
56. Falagas, M. E., Rafailidis, P. I., Kasiakou, S. K., Hatzopoulou, P., and Michalopoulos, A. (2006b). Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin. Microbiol. Infect. 12, 1227-1230.
57. Ferry, T., Uçkay, I., Vaudaux, P., François, P., Schrenzel, J., Harbarth, S., Laurent, F., Bernard, L., Vandenesch, F., Etienne, J., et al. (2010). Risk factors for treatment failure in orthopedic device-related methicillin-resistant Staphylococcus aureus infection. Eur. J. Clin. Microbiol. Infect. Dis. 29, 171-180.
58. Forgacs, P., Wengenack, N. L., Hall, L., Zimmerman, S. K., Silverman, M. L., and Roberts, G. D. (2009). Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob. Agents Chemother. 53, 4789-4793.
59. Forrest, G. N., and Tamura, K. (2010). Rifampin Combination Therapy for Nonmycobacterial Infections. Clin Microbiol Rev 23, 14-34.
60. Frye, J. G., and Jackson, C. R. (2013). Genetic mechanisms of antimicrobial resistance identified in Salmonella enterica, Escherichia coli, and Enteroccocus spp. isolated from U.S. food animals. Front Microbiol 4, 135.
61. Fujino, T., Amari, Y., Mohri, M., Noma, M., and Yamamoto, H. (2009). MRSA tricuspid valve infective endocarditis with multiple embolic lung abscesses treated by combination therapy of vancomycin, rifampicin, and sulfamethoxazole/trimethoprim. J Cardiol 53, 146- 149.
62. Fulnecky, E. J., Wright, D., Scheld, W. M., Kanawati, L., and Shoham, S. (2005). Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. J. Infect. 51, e249-251.
63. Garnacho-Montero, J., Ortiz-Leyba, C., Jiménez-Jiménez, F. J., Barrero-Almodóvar, A. E., García-Garmendia, J. L., Bernabeu-WittelI, M., Gallego-Lara, S. L., and Madrazo-Osuna, J. (2003). Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin. Infect. Dis. 36, 1111-1118.
64. Glupczynski, Y., Huang, T.-D., Berhin, C., Claeys, G., Delmée, M., Ide, L., Ieven, G., Pierard, D., Rodriguez-Villalobos, H., Struelens, M., et al. (2007). In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units. Eur. J. Clin. Microbiol. Infect. Dis. 26, 777-783.
65. Godtfredsen, W., Roholt, K., and Tybring, L. (1962). Fucidin: a new orally active antibiotic. Lancet 1, 928-931.
66. Goldberg, E., Paul, M., Talker, O., Samra, Z., Raskin, M., Hazzan, R., Leibovici, L., and Bishara, J. (2010). Co-trimoxazole versus vancomycin for the treatment of methicillinresistant Staphylococcus aureus bacteraemia: a retrospective cohort study. J. Antimicrob. Chemother. 65, 1779-1783.
67. De Górgolas, M., Avilés, P., Verdejo, C., and Fernández Guerrero, M. L. (1995). Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob. Agents Chemother. 39, 953-957.
68. Gould, C. V., Fishman, N. O., Nachamkin, I., and Lautenbach, E. (2004). Chloramphenicol resistance in vancomycin-resistant enterococcal bacteremia: impact of prior fluoroquinolone use? Infect Control Hosp Epidemiol 25, 138-145.
69. Graninger, W. (2003). Pivmecillinam--therapy of choice for lower urinary tract infection. Int. J. Antimicrob. Agents 22 Suppl 2, 73-78.
70. Grim, S. A., Rapp, R. P., Martin, C. A., and Evans, M. E. (2005). Trimethoprimsulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 25, 253-264.
71. Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 52, e103-120.
72. Gupta, N. D., Smith, R. E., and Balakrishnan, I. (2009). Clinical efficacy of temocillin. J. Antimicrob. Chemother. 64, 431-433.
73. Heintz, B. H., Halilovic, J., and Christensen, C. L. (2010). Vancomycin-resistant enterococcal urinary tract infections. Pharmacotherapy 30, 1136-1149.
74. Hidron, A. I., Low, C. E., Honig, E. G., and Blumberg, H. M. (2009). Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect Dis 9, 384-392.
75. Howden, B. P., and Grayson, M. L. (2006). Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin. Infect. Dis. 42, 394-400.
76. Huang, G., Yu, D., Zhu, Z., Zhao, H., Wang, P., Gray, G. C., Meng, L., and Xu, W. (2013). Outbreak of febrile respiratory illness associated with human adenovirus type 14p1 in Gansu Province, China. Influenza Other Respi Viruses.
77. Jansåker, F., Frimodt-Møller, N., Sjögren, I., and Dahl Knudsen, J. (2014). Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. J. Antimicrob. Chemother. 69, 769-772.
78. Jiménez-Mejías, M. E., Pichardo-Guerrero, C., Márquez-Rivas, F. J., Martín-Lozano, D., Prados, T., and Pachón, J. (2002). Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 21, 212-214.
79. De Jongh, R., Hens, R., Basma, V., Mouton, J. W., Tulkens, P. M., and Carryn, S. (2008). Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J. Antimicrob. Chemother. 61, 382-388.
80. Kallel, H., Hergafi, L., Bahloul, M., Hakim, A., Dammak, H., Chelly, H., Hamida, C. B., Chaari, A., Rekik, N., and Bouaziz, M. (2007). Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 33, 1162-1167.
81. Karageorgopoulos, D. E., Miriagou, V., Tzouvelekis, L. S., Spyridopoulou, K., and Daikos, G. L. (2012). Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J. Antimicrob. Chemother. 67, 2777-2779.
82. Kasiakou, S. K., Fragoulis, K., Tzagarakis, G., Mistidis, P., Kapaskelis, A., and Falagas, M. E. (2005a). Cure of multidrug-resistant Acinetobacter baumannii fixation device-related orthopedic infections in two patients with intravenous colistin. Microb. Drug Resist. 11, 287- 289.
83. Kasiakou, S. K., Michalopoulos, A., Soteriades, E. S., Samonis, G., Sermaides, G. J., and Falagas, M. E. (2005b). Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob. Agents Chemother. 49, 3136-3146.
84. Katopodis, G. D., Grivea, I. N., Tsantsaridou, A. J., Pournaras, S., Petinaki, E., and Syrogiannopoulos, G. A. (2010). Fusidic acid and clindamycin resistance in communityassociated, methicillin-resistant Staphylococcus aureus infections in children of Central Greece. BMC Infect. Dis. 10, 351.
85. Kawada, H., Yamazato, M., Shinozawa, Y., Suzuki, K., Otani, S., Ouchi, M., and Miyairi, M. (2008). [Achievement of sputum culture negative conversion by minocycline in a case with extensively drug-resistant pulmonary tuberculosis]. Kekkaku 83, 725-728.
86. Kefala-Agoropoulou, K., Protonotariou, E., Vitti, D., Sarafidou, S., Anastasiou, A., Kollios, K., and Roilides, E. (2010). Life-threatening infection due to community-acquired methicillinresistant Staphylococcus aureus: case report and review. Eur. J. Pediatr. 169, 47-53.
87. Klevens, R. M., Morrison, M. A., Nadle, J., Petit, S., Gershman, K., Ray, S., Harrison, L. H., Lynfield, R., Dumyati, G., Townes, J. M., et al. (2007). Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298, 1763-1771.
88. Kofteridis, D. P., Alexopoulou, C., Valachis, A., Maraki, S., Dimopoulou, D., Georgopoulos, D., and Samonis, G. (2010). Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin. Infect. Dis. 51, 1238-1244.
89. Komura, S., and Kurahashi, K. (1979). Partial purification and properties of L-2,4-diaminobutyric acid activating enzyme from a polymyxin E producing organism. J. Biochem. 86, 1013-1021.
90. Kontopidou, F., Giamarellou, H., Katerelos, P., Maragos, A., Kioumis, I., Trikka-Graphakos, E., Valakis, C., Maltezou, H. C., and Group for the Study of KPC-producing Klebsiella pneumoniae infections in intensive care units (2014). Infections caused by carbapenemresistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multicentre study on clinical outcome and therapeutic options. Clin. Microbiol. Infect. 20, O117- 123.
91. Koomanachai, P., Tiengrim, S., Kiratisin, P., and Thamlikitkul, V. (2007). Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. International Journal of Infectious Diseases 11, 402-406.
92. Lautenbach, E., Gould, C. V., LaRosa, L. A., Marr, A. M., Nachamkin, I., Bilker, W. B., and Fishman, N. O. (2004). Emergence of resistance to chloramphenicol among vancomycinresistant enterococcal (VRE) bloodstream isolates. Int. J. Antimicrob. Agents 23, 200-203.
93. Lautenbach, E., Schuster, M. G., Bilker, W. B., and Brennan, P. J. (1998). The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin. Infect. Dis. 27, 1259-1265.
94. Lawlor, M. T., Sullivan, M. C., Levitz, R. E., Quintiliani, R., and Nightingale, C. (1990). Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline. J. Infect. Dis. 161, 812-814.
95. Leclercq, R., Soussy, C. J., Weber, P., Moniot-Ville, N., Dib, C., and Groupe d'Etude Multicentrique (2003). [In vitro activity of the pristinamycin against the isolated staphylococci in the french hospitals in 1999-2000]. Pathol. Biol. 51, 400-404.
96. Lee, S.-Y., Park, Y.-J., Yu, J. K., Jung, S., Kim, Y., Jeong, S. H., and Arakawa, Y. (2012). Prevalence of acquired fosfomycin resistance among extended-spectrum β-lactamaseproducing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3. J. Antimicrob. Chemother. 67, 2843-2847.
97. Lee, W.-S., Chen, Y.-C., Chen, H.-P., Chen, T.-H., and Cheng, C.-Y. (2013). Vertebral osteomyelitis caused by vancomycin-tolerant methicillin-resistant Staphylococcus aureus bacteremia: Experience with teicoplanin plus fosfomycin combination therapy. J Microbiol Immunol Infect.
98. Levitz, R. E., Dudley, M. N., Quintiliani, R., Mullany, L. D., and Nightingale, C. H. (1984). Cerebrospinal fluid penetration of trimethoprim-sulphamethoxazole in two patients with gram-negative bacillary meningitis. J. Antimicrob. Chemother. 13, 400-401.
99. Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., and Paterson, D. L. (2006). Colistin: the re-emerging antibiotic for multidrug-resistant Gramnegative bacterial infections. Lancet Infect Dis 6, 589-601.
100. Linden, P. K., Kusne, S., Coley, K., Fontes, P., Kramer, D. J., and Paterson, D. (2003). Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin. Infect. Dis. 37, e154-160.
101. Livermore, D. M., Hope, R., Fagan, E. J., Warner, M., Woodford, N., and Potz, N. (2006). Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J. Antimicrob. Chemother. 57, 1012-1014.
102. Livermore, D. M., and Tulkens, P. M. (2009). Temocillin revived. J. Antimicrob. Chemother. 63, 243-245.
103. Livermore, D. M., Warner, M., Mushtaq, S., Doumith, M., Zhang, J., and Woodford, N. (2011). What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. International Journal of Antimicrobial Agents 37, 415-419.
104. Long, K. S., and Vester, B. (2012). Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob. Agents Chemother. 56, 603-612.
105. Lu, Q., Luo, R., Bodin, L., Yang, J., Zahr, N., Aubry, A., Golmard, J.-L., Rouby, J.-J., and Nebulized Antibiotics Study Group (2012). Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 117, 1335-1347.
106. Markou, N., Apostolakos, H., Koumoudiou, C., Athanasiou, M., Koutsoukou, A., Alamanos, I., and Gregorakos, L. (2003). Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 7, R78-83.
107. Markowitz, N., Quinn, E. L., and Saravolatz, L. D. (1992). Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann. Intern. Med. 117, 390-398.
108. Martínez-Aguilar, G., Hammerman, W. A., Mason, E. O., and Kaplan, S. L. (2003). Clindamycin treatment of invasive infections caused by community-acquired, methicillinresistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr. Infect. Dis. J. 22, 593-598.
109. Mastoraki, A., Douka, E., Kriaras, I., Stravopodis, G., Manoli, H., and Geroulanos, S. (2008). Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients. Surg Infect (Larchmt) 9, 153-160.
110. McGehee, R. F., Smith, C. B., Wilcox, C., and Finland, M. (1968). Comparative studies of antibacterial activity in vitro and absorption and excretion of lincomycin and clinimycin. Am. J. Med. Sci. 256, 279-292.
111. Mehta, N. J., Khan, I. A., Mehta, R. N., and Gulati, A. (2000). Stenotrophomonas maltophilia endocarditis of prosthetic aortic valve: report of a case and review of literature. Heart Lung 29, 351-355.
112. Merkier, A. K., Rodríguez, M. C., Togneri, A., Brengi, S., Osuna, C., Pichel, M., Cassini, M. H., Serratia marcescens Argentinean Collaborative Group, and Centrón, D. (2013). Outbreak of a cluster with epidemic behavior due to Serratia marcescens after colistin administration in a hospital setting. J. Clin. Microbiol. 51, 2295-2302.
113. Messina, A. F., Namtu, K., Guild, M., Dumois, J. A., and Berman, D. M. (2011). Trimethoprim-sulfamethoxazole therapy for children with acute osteomyelitis. Pediatr. Infect. Dis. J. 30, 1019-1021.
114. Michalopoulos, A. S., and Falagas, M. E. (2014). Inhaled antibiotics in mechanically ventilated patients. Minerva Anestesiol 80, 236-244.
115. Michalopoulos, A., Virtzili, S., Rafailidis, P., Chalevelakis, G., Damala, M., and Falagas, M. E. (2010). Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin. Microbiol. Infect. 16, 184-186.
116. Mirakhur, A., Gallagher, M. J., Ledson, M. J., Hart, C. A., and Walshaw, M. J. (2003). Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J. Cyst. Fibros. 2, 19-24.
117. Mitnick, C. D., Shin, S. S., Seung, K. J., Rich, M. L., Atwood, S. S., Furin, J. J., Fitzmaurice, G. M., Alcantara Viru, F. A., Appleton, S. C., Bayona, J. N., et al. (2008). Comprehensive treatment of extensively drug-resistant tuberculosis. N. Engl. J. Med. 359, 563-574.
118. Mohamed, A. F., Karaiskos, I., Plachouras, D., Karvanen, M., Pontikis, K., Jansson, B., Papadomichelakis, E., Antoniadou, A., Giamarellou, H., Armaganidis, A., et al. (2012). Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob. Agents Chemother. 56, 4241-4249.
119. Moran, G. J., Krishnadasan, A., Gorwitz, R. J., Fosheim, G. E., McDougal, L. K., Carey, R. B., Talan, D. A., and EMERGEncy ID Net Study Group (2006). Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355, 666- 674.
120. Moreno, F., Jorgensen, J. H., and Weiner, M. H. (1994). An old antibiotic for a new multipleresistant Enterococcus faecium? Diagn. Microbiol. Infect. Dis. 20, 41-43.
121. Motaouakkil, S., Charra, B., Hachimi, A., Nejmi, H., Benslama, A., Elmdaghri, N., Belabbes, H., and Benbachir, M. (2006). Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J. Infect. 53, 274-278.
122. Mouton, J. W., Ambrose, P. G., Canton, R., Drusano, G. L., Harbarth, S., MacGowan, A., Theuretzbacher, U., and Turnidge, J. (2011). Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist. Updat. 14, 107-117.
123. Muhammed Ameen, S., Rolain, J.-M., Le Poullain, M.-N., Roux, V., Raoult, D., and Drancourt, M. (2014). Serum concentration of co-trimoxazole during a high-dosage regimen. J. Antimicrob. Chemother. 69, 757-760.
124. Murray, R. J., Pearson, J. C., Coombs, G. W., Flexman, J. P., Golledge, C. L., Speers, D. J., Dyer, J. R., McLellan, D. G., Reilly, M., Bell, J. M., et al. (2008). Outbreak of invasive methicillin-resistant Staphylococcus aureus infection associated with acupuncture and joint injection. Infect Control Hosp Epidemiol 29, 859-865.
125. Nadler, J. P., Berger, J., Nord, J. A., Cofsky, R., and Saxena, M. (1991). Amoxicillinclavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 99, 1025-1026.
126. Nakaya, H., Yasuhara, A., Yoshimura, K., Oshihoi, Y., Izumiya, H., and Watanabe, H. (2003). Life-threatening infantile diarrhea from fluoroquinolone-resistant Salmonella enterica typhimurium with mutations in both gyrA and parC. Emerging Infect. Dis. 9, 255-257.
127. Nather, A., David, V., Hee, H. T., and Thambiah, J. (2005). Pyogenic vertebral osteomyelitis: a review of 14 cases. J Orthop Surg (Hong Kong) 13, 240-244.
128. Navarro-San Francisco, C., Mora-Rillo, M., Romero-Gómez, M. P., Moreno-Ramos, F., Rico-Nieto, A., Ruiz-Carrascoso, G., Gómez-Gil, R., Arribas-López, J. R., Mingorance, J., and Paño-Pardo, J. R. (2013). Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin. Microbiol. Infect. 19, E72-79.
129. Nelson, M. L., and Levy, S. B. (2011). The history of the tetracyclines. Annals of the New York Academy of Sciences 1241, 17-32.
130. Neuner, E. A., Sekeres, J., Hall, G. S., and van Duin, D. (2012). Experience with Fosfomycin for Treatment of Urinary Tract Infections Due to Multidrug-Resistant Organisms. Antimicrob Agents Chemother 56, 5744-5748.
131. Ng, J., and Gosbell, I. B. (2005). Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp. J. Antimicrob. Chemother. 55, 1008-1012.
132. Nguyen, S., Pasquet, A., Legout, L., Beltrand, E., Dubreuil, L., Migaud, H., Yazdanpanah, Y., and Senneville, E. (2009). Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin. Microbiol. Infect. 15, 1163-1169.
133. Nicolle, L. E., and Mulvey, M. R. (2007). Successful treatment of ctx-m ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam. Scand. J. Infect. Dis. 39, 748-749.
134. Norris, A. H., Reilly, J. P., Edelstein, P. H., Brennan, P. J., and Schuster, M. G. (1995). Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin. Infect. Dis. 20, 1137-1144.
135. O'Neill, B. J., Hirpara, K. M., and Kaar, T. K. (2011). Successful Treatment of Chronic Osteomyelitis of the Radius. ISRN Pediatr 2011.
136. Oostdijk, E. A. N., Smits, L., de Smet, A. M. G. A., Leverstein-van Hall, M. A., Kesecioglu, J., and Bonten, M. J. M. (2013). Colistin resistance in gram-negative bacteria during prophylactic topical colistin use in intensive care units. Intensive Care Med 39, 653-660.
137. Park, Y. K., Choi, J. Y., Shin, D., and Ko, K. S. (2011). Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in Acinetobacter baumannii. Int. J. Antimicrob. Agents 37, 525-530.
138. Patel, S. N., Memari, N., Shahinas, D., Toye, B., Jamieson, F. B., and Farrell, D. J. (2013). Linezolid resistance in Enterococcus faecium isolated in Ontario, Canada. Diagn. Microbiol. Infect. Dis. 77, 350-353.
139. Pea, F., and Viale, P. (2007). Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections. Expert Rev Anti Infect Ther 5, 255-270.
140. Pérez Mato, S., Robinson, S., and Bégué, R. E. (1999). Vancomycin-resistant Enterococcus faecium meningitis successfully treated with chloramphenicol. Pediatr. Infect. Dis. J. 18, 483-484.
141. Pfaller, M. A., Castanheira, M., Sader, H. S., and Jones, R. N. (2010). Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. Int. J. Antimicrob. Agents 35, 282-287.
142. Pitout, J. D. D., and Laupland, K. B. (2008). Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8, 159-166.
143. Pogue, J. M., Marchaim, D., Kaye, D., and Kaye, K. S. (2011). Revisiting "older" antimicrobials in the era of multidrug resistance. Pharmacotherapy 31, 912-921.
144. Pontikis, K., Karaiskos, I., Bastani, S., Dimopoulos, G., Kalogirou, M., Katsiari, M., Oikonomou, A., Poulakou, G., Roilides, E., and Giamarellou, H. (2014). Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrugresistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int. J. Antimicrob. Agents 43, 52-59.
145. Poulsen, H. O., Johansson, A., Granholm, S., Kahlmeter, G., and Sundqvist, M. (2013). High genetic diversity of nitrofurantoin- or mecillinam-resistant Escherichia coli indicates low propensity for clonal spread. J. Antimicrob. Chemother. 68, 1974-1977.
146. Pound, M. W., Tart, S. B., and Okoye, O. (2007). Multidrug-resistant Ewingella americana: a case report and review of the literature. Ann Pharmacother 41, 2066-2070.
147. Proctor, R. A. (2008). Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin. Infect. Dis. 46, 584-593.
148. Pulcini, C., Bush, K., Craig, W. A., Frimodt-Møller, N., Grayson, M. L., Mouton, J. W., Turnidge, J., Harbarth, S., Gyssens, I. C., and ESCMID Study Group for Antibiotic Policies (2012). Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin. Infect. Dis. 54, 268-274.
149. Pullukcu, H., Tasbakan, M., Sipahi, O. R., Yamazhan, T., Aydemir, S., and Ulusoy, S. (2007). Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int. J. Antimicrob. Agents 29, 62-65.
150. Quentin, C., Grobost, F., Fischer, I., Dutilh, B., Brochet, J. P., Jullin, J., Lagrange, I., Noury, P., Larribet, G., Andre, C., et al. (2001). [Antibiotic resistance of Staphylococcus aureus in urban experience: 6month study in Aquitaine]. Pathol. Biol. 49, 33-40.
151. Raz, R. (2012). Fosfomycin: an old--new antibiotic. Clin. Microbiol. Infect. 18, 4-7.
152. Reed, M. D., Stern, R. C., O'Riordan, M. A., and Blumer, J. L. (2001). The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 41, 645-654.
153. Reid, A. B., Daffy, J. R., Stanley, P., and Buising, K. L. (2010). Use of pristinamycin for infections by gram-positive bacteria: clinical experience at an Australian hospital. Antimicrob. Agents Chemother. 54, 3949-3952.
154. Ricaurte, J. C., Boucher, H. W., Turett, G. S., Moellering, R. C., Labombardi, V. J., and Kislak, J. W. (2001). Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia. Clin. Microbiol. Infect. 7, 17-21.
155. Rios, F. G., Luna, C. M., Maskin, B., Saenz Valiente, A., Lloria, M., Gando, S., Sosa, C., Baquero, S., Llerena, C., Petrati, C., et al. (2007). Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur. Respir. J. 30, 307-313.
156. Roberts, M. C. (2008). Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone resistance genes. FEMS Microbiology Letters 282, 147-159.
157. Rodríguez, A., Gallego, A., Olay, T., and Mata, J. M. (1977). Bacteriological evaluation of fosfomycin in clinical studies. Chemotherapy 23 Suppl 1, 247-258.
158. Rodriguez-Villalobos, H., Malaviolle, V., Frankard, J., de Mendonça, R., Nonhoff, C., and Struelens, M. J. (2006). In vitro activity of temocillin against extended spectrum betalactamase-producing Escherichia coli. J. Antimicrob. Chemother. 57, 771-774.
159. Rolain, J.-M., Diene, S. M., Kempf, M., Gimenez, G., Robert, C., and Raoult, D. (2013). Real-time sequencing to decipher the molecular mechanism of resistance of a clinical pandrug-resistant Acinetobacter baumannii isolate from Marseille, France. Antimicrob. Agents Chemother. 57, 592-596.
160. Rolain, J.-M., Roch, A., Castanier, M., Papazian, L., and Raoult, D. (2011). Acinetobacter baumannii resistant to colistin with impaired virulence: a case report from France. J. Infect. Dis. 204, 1146-1147.
161. Roualdes, G., Lartigue, C., Boudigue, M. D., and Maissin, F. (1985). [Infection of the valves of CSF shunts. Results of local and general antibiotic treatment in 6 cases]. Neurochirurgie 31, 390-394.
162. Ruhe, J. J., and Menon, A. (2007). Tetracyclines as an Oral Treatment Option for Patients with Community Onset Skin and Soft Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother 51, 3298-3303.
163. Ruhe, J. J., Monson, T., Bradsher, R. W., and Menon, A. (2005). Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin. Infect. Dis. 40, 1429-1434.
164. Ruhe, J. J., Smith, N., Bradsher, R. W., and Menon, A. (2007). Community-onset methicillinresistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin. Infect. Dis. 44, 777-784.
165. Ruparelia, N., Atkins, B. L., Hemingway, J., Berendt, A. R., and Byren, I. (2008). Pristinamycin as adjunctive therapy in the management of Gram-positive multi-drug resistant organism (MDRO) osteoarticular infection. J. Infect. 57, 191-197.
166. Sandegren, L., Lindqvist, A., Kahlmeter, G., and Andersson, D. I. (2008). Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. J. Antimicrob. Chemother. 62
167. Scapellato, P. G., Ormazabal, C., Scapellato, J. L., and Bottaro, E. G. (2005). Meningitis due to vancomycin-resistant Enterococcus faecium successfully treated with combined intravenous and intraventricular chloramphenicol. J. Clin. Microbiol. 43, 3578-3579.
168. Schwartz, B. S., Graber, C. J., Diep, B. A., Basuino, L., Perdreau-Remington, F., and Chambers, H. F. (2009). Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300. Clin. Infect. Dis. 48, 1483-1484.
169. Seligman, S. J., Madhavan, T., and Alcid, D. (1973). Trimethoprim-sulfamethoxazole in the treatment of bacterial endocarditis. J. Infect. Dis. 128, Suppl:754-761 p.
170. Senol, S., Tasbakan, M., Pullukcu, H., Sipahi, O. R., Sipahi, H., Yamazhan, T., Arda, B., and Ulusoy, S. (2010). Carbapenem versus fosfomycin tromethanol in the treatment of extendedspectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother 22, 355-357.
171. Seppälä, H., Klaukka, T., Vuopio-Varkila, J., Muotiala, A., Helenius, H., Lager, K., and Huovinen, P. (1997). The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N. Engl. J. Med. 337, 441-446.
172. Shafqat, S. H., Shah, S. A., and Seyed, S. A. (1971). Bacterial endocarditis over prosthetic valves treated with trimethoprim-sulphamethoxazole combination. Br Heart J 33, 974-976.
173. Shean, K., Streicher, E., Pieterson, E., Symons, G., van Zyl Smit, R., Theron, G., Lehloenya, R., Padanilam, X., Wilcox, P., Victor, T. C., et al. (2013). Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa. PLoS One 8, e63057.
174. Siberry, G. K., Tekle, T., Carroll, K., and Dick, J. (2003). Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin. Infect. Dis. 37, 1257-1260.
175. Silbermann, M. H., Gyssens, I. C., Wielenga, J. J., Endtz, H. P., and Löwenberg, B. (1995). [A patient with acute leukemia and meningitis caused by Staphylococcus epidermidis treated with fosfomycin]. Ned Tijdschr Geneeskd 139, 2498-2501.
176. Slocombe, B., Basker, M. J., Bentley, P. H., Clayton, J. P., Cole, M., Comber, K. R., Dixon, R. A., Edmondson, R. A., Jackson, D., Merrikin, D. J., et al. (1981). BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans. Antimicrob. Agents Chemother. 20, 38-46.
177. Song, J. Y., Lee, J., Heo, J. Y., Noh, J. Y., Kim, W. J., Cheong, H. J., and Hwang, I. S. (2008). Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. International Journal of Antimicrobial Agents 32, 281-284.
178. Søraas, A., Sundsfjord, A., Jørgensen, S. B., Liestøl, K., and Jenum, P. A. (2014). High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli. PLoS ONE 9, e85889.
179. Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., and Edwards, J. E. (2004). Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38, 1279-1286.
180. Stein, A., Bataille, J. F., Drancourt, M., Curvale, G., Argenson, J. N., Groulier, P., and Raoult, D. (1998). Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob. Agents Chemother. 42, 3086-3091.
181. Stevens, D. L., Bisno, A. L., Chambers, H. F., Dellinger, E. P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, S. L., Montoya, J. G., and Wade, J. C. (2014). Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. Clin. Infect. Dis.
182. Suárez, J. E., and Mendoza, M. C. (1991). Plasmid-encoded fosfomycin resistance. Antimicrob. Agents Chemother. 35, 791-795.
183. Sullivan, A., Edlund, C., and Nord, C. E. (2001). Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 1, 101-114.
184. Tamer, M. A., and Bray, J. D. (1982). Trimethoprim-sulfamethoxazole treatment of multiantibiotic-resistant staphylococcal endocarditis and meningitis. Clin Pediatr (Phila) 21, 125-126.
185. Tasbakan, M. I., Pullukcu, H., Sipahi, O. R., Yamazhan, T., and Ulusoy, S. (2012). Nitrofurantoin in the treatment of extended-spectrum β-lactamase-producing Escherichia colirelated lower urinary tract infection. Int. J. Antimicrob. Agents 40, 554-556.
186. Taşbakan, M. S., Pullukçu, H., Ekren, P. K., Oz, A. T., Midilli, M., Aydemir, S., Gürgün, A., Başoğlu, O. K., and Bacakoğlu, F. (2009). [Colistin use in ventilator-associated pneumonia due to panresistant Pseudomonas aeruginosa and Acinetobacter baumannii]. Mikrobiyol Bul 43, 61-70.
187. Tascini, C., Gemignani, G., Palumbo, F., Leonildi, A., Tedeschi, A., Lambelet, P., Lucarini, A., Piaggesi, A., and Menichetti, F. (2006). Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J Chemother 18, 648-651.
188. Taylor, S. E., Paterson, D. L., and Yu, V. L. (1998). Treatment options for chronic prostatitis due to vancomycin-resistant Enterococcus faecium. Eur. J. Clin. Microbiol. Infect. Dis. 17, 798-800.
189. Titelman, E., Iversen, A., Kalin, M., and Giske, C. G. (2012). Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamaseproducing Escherichia coli and Klebsiella pneumoniae. Microb. Drug Resist. 18, 189-192.
190. Tobeña Rué, M., Coll Usandizaga, F., García Fontecha, C., Bartolomé Comas, R., and Moraga Llop, F. A. (2009). [Necrotizing fasciitis due to community-acquired pantonvalentine leukocidin methicillin resistant Staphylococcus aureus]. An Pediatr (Barc) 70, 374- 378.
191. Trzcinski, K., Cooper, B. S., Hryniewicz, W., and Dowson, C. G. (2000). Expression of resistance to tetracyclines in strains of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 45, 763-770.
192. Tsukamura, M., Mizuno, S., and Toyama, H. (1983). [Combined effect of minocycline with antitubercular agents on Mycobacterium tuberculosis: in vitro study]. Kekkaku 58, 665-667.
193. Tumbarello, M., De Pascale, G., Trecarichi, E. M., De Martino, S., Bello, G., Maviglia, R., Spanu, T., and Antonelli, M. (2013). Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest 144, 1768-1775.
194. Turnidge, J. (1999). Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. Int. J. Antimicrob. Agents 12 Suppl 2, S23-34.
195. Tuzuner-Oncul, A. M., Ungor, C., Dede, U., and Kisnisci, R. S. (2009). Methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107, e1-4.
196. Udo, E. E., Al-Sweih, N., Mokaddas, E., Johny, M., Dhar, R., Gomaa, H. H., Al-Obaid, I., and Rotimi, V. O. (2006). Antibacterial resistance and their genetic location in MRSA isolated in Kuwait hospitals, 1994-2004. BMC Infect. Dis. 6, 168.
197. Van der Veen, E. L., Schilder, A. G. M., Timmers, T. K., Rovers, M. M., Fluit, A. C., Bonten, M. J., and Leverstein-van Hall, M. A. (2009). Effect of long-term trimethoprim/sulfamethoxazole treatment on resistance and integron prevalence in the intestinal flora: a randomized, double-blind, placebo-controlled trial in children. J. Antimicrob. Chemother. 63, 1011-1016.
198. Wachi, M., Doi, M., Tamaki, S., Park, W., Nakajima-Iijima, S., and Matsuhashi, M. (1987). Mutant isolation and molecular cloning of mre genes, which determine cell shape, sensitivity to mecillinam, and amount of penicillin-binding proteins in Escherichia coli. J. Bacteriol. 169, 4935-4940.
199. Walker, B., Barrett, S., Polasky, S., Galaz, V., Folke, C., Engström, G., Ackerman, F., Arrow, K., Carpenter, S., Chopra, K., et al. (2009). Environment. Looming global-scale failures and missing institutions. Science 325, 1345-1346.
200. Wang, J.-L., Tang, H.-J., Hsieh, P.-H., Chiu, F.-Y., Chen, Y.-H., Chang, M.-C., Huang, C.-T., Liu, C.-P., Lau, Y.-J., Hwang, K.-P., et al. (2012). Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 40, 103-107.
201. Wasyl, D., Hoszowski, A., Zajac, M., and Szulowski, K. (2013). Antimicrobial resistance in commensal Escherichia coli isolated from animals at slaughter. Front Microbiol 4.
202. Williamson, D. A., Monecke, S., Heffernan, H., Ritchie, S. R., Roberts, S. A., Upton, A., Thomas, M. G., and Fraser, J. D. (2014). A cautionary tale: High usage of topical fusidic acid and rapid clonal expansion of fusidic acid-resistant Staphylococcus aureus. Clin. Infect. Dis.
203. Wolfe, C. R. (2011). Case Report: Treatment of Chronic Osteomyelitis. Clin Infect Dis. 52
204. Wood, J. B., Smith, D. B., Baker, E. H., Brecher, S. M., and Gupta, K. (2012). Has the emergence of community-associated methicillin-resistant Staphylococcus aureus increased trimethoprim-sulfamethoxazole use and resistance?: a 10-year time series analysis. Antimicrob. Agents Chemother. 56, 5655-5660.
205. Xu, H.-B., Jiang, R.-H., and Xiao, H.-P. (2012). Clofazimine in the treatment of multidrugresistant tuberculosis. Clin. Microbiol. Infect. 18, 1104-1110.
206. Xu, H., Miao, V., Kwong, W., Xia, R., and Davies, J. (2011). Identification of a novel fosfomycin resistance gene (fosA2) in Enterobacter cloacae from the Salmon River, Canada. Lett. Appl. Microbiol. 52, 427-429.
207. Xu, X., Chen, C., Lin, D., Guo, Q., Hu, F., Zhu, D., Li, G., and Wang, M. (2013). The fosfomycin resistance gene fosB3 is located on a transferable, extrachromosomal circular intermediate in clinical Enterococcus faecium isolates. PLoS ONE 8, e78106.
208. Yoo, J.-W., Lyu, J., Lee, S. D., Kim, W. S., Kim, D. S., and Shim, T. S. (2013). Clinical experience of using clofazimine to treat multidrug-resistant tuberculosis [Correspondence]. Int. J. Tuberc. Lung Dis. 17, 1243-1244.
209. Zahar, J.-R., Lortholary, O., Martin, C., Potel, G., Plesiat, P., and Nordmann, P. (2009). Addressing the challenge of extended-spectrum beta-lactamases. Curr Opin Investig Drugs 10, 172-180.
210. Zhanel, G. G., Laing, N. M., Nichol, K. A., Palatnick, L. P., Noreddin, A., Hisanaga, T., Johnson, J. L., Hoban, D. J., and NAVRESS Group (2003). Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). J. Antimicrob. Chemother. 52, 382-388.